The Host Country Agreement marks a significant milestone in Kenya’s growing role as a regional hub for health innovation and biotechnology.
Officials said the partnership will enhance collaboration in vaccine development, public health research, and pandemic preparedness while positioning Kenya at the forefront of Africa’s healthcare transformation.
The agreement was signed during a high-level ceremony attended by senior government officials, representatives from IVI, and stakeholders from the health and scientific community.
Leaders described the partnership as a strategic investment in Africa’s future health security.
Speaking during the event, government officials said the establishment of the IVI office in Kenya demonstrates international confidence in the country’s scientific capacity, political stability and expanding healthcare infrastructure.
Also Read
The office is also expected to support implementation of the AVEC Africa Project, an initiative focused on accelerating vaccine manufacturing and equitable distribution across African countries.
Health sector leaders noted that Africa still imports the majority of its vaccines, exposing many nations to supply shortages during global emergencies such as the COVID-19 pandemic.
They said the new partnership seeks to address those challenges by strengthening local and regional vaccine ecosystems.
The IVI Kenya office will facilitate collaboration between local researchers, universities, pharmaceutical companies and global health institutions.
It is expected to support training, technology transfer, policy development and scientific research aimed at improving vaccine access and disease prevention.
Officials further stated that the project aligns with Kenya’s broader ambition of becoming a center for medical innovation and pharmaceutical manufacturing in Africa.
The government has in recent years intensified efforts to attract global health investments and expand local production of essential medicines and vaccines.
IVI representatives praised Kenya for its commitment to advancing healthcare and scientific research, saying the country offers a strategic gateway for expanding vaccine initiatives across Africa.
They emphasized the importance of partnerships in tackling emerging infectious diseases and improving immunization coverage.
Experts believe the agreement could also create employment opportunities for scientists, researchers and healthcare professionals while attracting additional international funding into the country’s biomedical sector.
Public health stakeholders welcomed the move, arguing that stronger vaccine research and manufacturing capacity in Africa is essential in reducing dependence on external supplies and ensuring faster responses during disease outbreaks.
The establishment of the IVI Kenya Country and AVEC Africa Project Office is expected to begin operations soon, with officials expressing optimism that the initiative will contribute to a healthier and more resilient Africa.
